Purpose: As corneal stromal cells (keratocytes) become activated before transition to the fibroblastic repair phenotype in response to injury (in situ) or serum (in culture), the corneal crystallins, transketolase (TKT) and aldehyde dehydrogenase (ALDH1A1), are lost. The authors previously showed that the serum cytokine plateletderived growth factor-BB (PDGF), but not transforming growth factor beta2 (TGF-beta2), stimulates TKT loss. The goal of this study was to further define the molecular mechanisms for PDGFstimulated loss of crystallins to elucidate the pathway for keratocyte activation.
I njury to connective tissues stimulates a general repair response that shares common features across organ systems, including the skin, lung, or cornea. 1, 2 As part of this response, cells at the wound periphery become activated to proliferate and deposit a disorganized fibrotic extracellular matrix that seals off the damaged area. Fibrotic repair tissue can never reproduce the functions of the original tissue that it replaces; however, under some conditions, the repair response can take on a more regenerative character. Understanding the molecular pathways controlling fibrotic repair in its many manifestations may enable the design of strategies to improve its regenerative character. [3] [4] [5] [6] In the cornea, repair cells seem to be derived, at least in part, from resident keratocytes of the corneal stroma. [7] [8] [9] The cornea provides an ideal model for examining activating events that lead to repair phenotypes because corneal stromal cells can be isolated from other cell types and cultured without exposure to serum. 4, 10 We, and others, have characterized the fibrotic progression in the cornea as a multistep process that begins when resident keratocytes of the corneal stroma acquire "activation competency" and assume a "fibroblast" phenotype, which can progress to a more fibrotic form of repair. When corneal stromal cells are freshly isolated from the cornea and plated in culture without serum, they remain quiescent, which is characterized by being nonproliferative, having a dendritic morphology, 11 and maintaining expression of the proteoglycans characteristic of a transparent cornea. 12 When exposed to serum however, they take on a phenotype over a period of 3 days that is very similar to that of fibroblasts seen in repair tissue. 10, [13] [14] [15] [16] The transition is characterized by (1) a change in cell shape from dendritic to spindle-shaped associated with reorganization of the actin cytoskeleton to form stress fibers, 16 (2) induction of a5-integrin expression and its heterodimerization with b1-integrin to form the fibronectin receptor, 11, 16 (3) deposition of a repair-type extracellular matrix through induced expression of new molecule such as fibronectin and SPARC, 16, 17 and (4) competence to activate an IL-1a autocrine feedback loop essential for the control of collagenase expression and subsequent repair tissue remodeling. [18] [19] [20] In the cornea, the early repair transition from keratocyte to fibroblast is also associated with a loss of specific markers. These include secreted keratan sulfate proteoglycans, such as prostaglandin D synthase, 21, 22 and members of a group of highly prevalent intracellular proteins called "corneal crystallins" by analogy to the crystallins of the eye's lens. The corneal crystallins provide protection against oxidative damage [23] [24] [25] and may also help confer transparency to the cells. 26, 27 The members of this family vary greatly among different species. 26, 27 Two proteins classified as corneal crystallins in the rabbit are the metabolic enzymes transketolase (TKT) and aldehyde dehydrogenase 1A1 (ALDH1A1). 26 Using a model of freshly isolated rabbit corneal keratocytes (RCK), we previously determined that the serum cytokine platelet-derived growth factor-BB (PDGF) stimulates loss of TKT. 28 We sought here to further define the molecular mechanisms for PDGF-stimulated keratocyte loss of corneal crystallins that serves to further understand the conversion of keratocytes into repair cells. Together our findings suggest that pharmacological agents that target PDGF signaling might be used to prevent TKT loss or stimulate TKT re-accumulation after corneal injury, thus improving the regenerative character of corneal repair.
MATERIALS AND METHODS

Cell Culture
Rabbit corneal stromal keratocytes (RCK) were isolated from the corneas of New Zealand White rabbits (Pel Freez Co, Rogers, AR) by collagenase digestion modified from a described method. 18 Previously, freshly isolated keratocytes were exposed to serum overnight to aid cell attachment. 29 Because serum has been shown to reduce TKT levels 28 and serum-induced effects would impact PDGF-induced effects on TKT levels, we modified the technique to maintain RCK in serum-free Dulbecco modified Eagle medium (Invitrogen-GIBCO, Carlsbad, CA) throughout the isolation. With this modified technique, PDGF-induced TKT reduction was noted on both a per cell basis (as previously shown 29 ) and when assessing equivalent protein levels ( Fig. 1 ). Briefly, epithelium was removed and then RCK were freed from the stroma by incubation in 5 mg/mL of bacterial collagenase for 1 hour at 37°C. RCK were pooled from 25 stromas, plated, and maintained throughout the culture period in serum-free Dulbecco modified Eagle medium supplemented with 50 U/mL of penicillin, 50 mg/mL of streptomycin, and 0.5 mg/mL of fungizone amphotericin B at 37°C under 95% humidity and 5% CO 2 . RCK were rinsed after 1 day in culture, and the following cell treatment reagents were added simultaneously to these original cultures and maintained with no change for 4 additional culture days unless otherwise indicated: 100 ng/mL of PDGF (R&D Systems, Minneapolis, MN); with or without 10 mM of Gleevec (also known as ST1571, CGP57148B) (Novartis, Basel, Switzerland), or various cell permeable inhibitors obtained from EMD4Biosciences (San Diego, CA): 10 mM of triciribine (Akt Inhibitor V) (does not inhibit PI3K), A, Representative immunoblot of cytoplasmic lysates probed for TKT or ALDH1A1 and GAPDH. GADPH was used to allow better separation from the ALDH1A1. Brackets indicate immunoblot of protein of interest associated with its control. Marker indicates 90 kDa molecular marker on TKT blot and 300 ng purified ALDH1A1 on ALDH1A1 blot. B, Graph of immunoblot data. Relative TKT or ALDH1A1 protein, a ratio of the TKT or ALDH1A1 to GAPDH band densities for each immunoblot (n = 3), expressed as average 6 SD. TKT, ALD-H1A1, and GAPDH bands are ;70 kDa, ;55 kDa, and ;37 kDa, respectively, based on molecular size markers (data not shown). *P , 0.05, PDGF (+) versus PDGF (2). 5 mM of sodium orthovanadate (Sigma, St. Louis, MO)]. Lysates were cleared by centrifugation, and protein concentrations were determined using a protein assay (BioRad, Hercules, CA) according to the manufacturer's instructions. Samples, 1 to 5 mg of total protein, were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis on 10% Tris-glycine gels (Bio-Rad) and electroblotted onto polyvinylidene difluoride (PVDF) membranes. The membranes were blocked with 5% dry milk in TBS/Tween20. Membranes probed with (1) 1:5000 of rabbit anti-human ALDH1A1 antibody or purified ALDH1A1 protein for control 30 in 1% dry milk, followed by incubation with horseradish peroxidase (HRP)-linked anti-chicken antibody to avoid cross-reacting with rabbit (Jackson ImmunoResearch, West Grove, PA); (2) 1:1000 of rabbit anti-mouse TKT antibody (a generous gift from Dr Joram Piatigorsky, National Eye Institute) in 1% dry milk, followed by incubation with HRPlinked anti-rabbit antibody (Jackson ImmunoResearch) and (3) 1:2000 of mouse anti-beta-actin or anti-GAPDH (Sigma) in 1% dry milk, followed by incubation with HRP-linked antimouse antibody (Jackson ImmunoResearch). HRP was visualized by enhanced chemiluminescence (Sigma). Blots were stripped (Pierce, Rockford, IL) of one set of antibodies, tested to ensure detection reagents were removed, and then reprobed with the next set of antibodies. Where indicated, the ;37 kDa GAPDH was used as an internal control, rather than the ;42 kDa beta-actin, to allow better separation between the band of interest and the control band or because the treatment has been shown to alter actin. 31 The specific band for the protein of interest was identified by its relative electrophoretic mobility with respect to the size standard. Specific binding was quantified by densitometry using Quantity One imaging software (BioRad). The protein levels were normalized to internal beta-actin or GAPDH. For immunoprecipitation, RCK lysate was mixed overnight with anti-TKT antibody, precipitated with Protein-G-Agarose (Roche) as per the manufacturers' instructions, and supernatants were probed as above with mouse anti-bovine ubiquitin (Millipore-Chemicon, Billerica, MA).
Quantitative Reverse Transcription-Polymerase Chain Reaction
Total RNA was extracted from the cells with a total aurum kit as per the manufacturer's instructions (BioRad). Total RNA was quantified spectrophotometrically at 260 nm and 10 ng/mL of RNA was reverse transcribed using the iScript cDNA Synthesis Kit (BioRad). One-tenth of the complementary DNA was subjected to quantitative reverse transcription-polymerase chain reaction using iQ SYBR Supermix (BioRad) and primers for 18S ribosomal RNA (Invitrogen) and primers for TKT on an iCycler (BioRad). We developed the TKT primers (TKT-F, 59-ATCATTGC-CAAGACCTTCAA-39; TKT-R, 59-GATGATCTGCT-CAGCCATGT-39) against mouse TKT (accession: BC055336; gi:33244004) base pair 782 to 883 that is shared by human (BC002433, gi:33876691). Reduction in TKT messenger RNA (mRNA) levels using these primers was confirmed with RCK treated for 4 days with serum (data not shown). Melt curves indicate that the primer set produced one product. TKT levels expressed as threshold cycles were normalized to an internal control, 18S. Relative TKT mRNA was calculated as 18S threshold cycles subtracted from TKT threshold cycles to the using iCycler iQ Optical System Software, version 3.0a (BioRad).
Data Presentation and Analysis
Immunoblot data presented graphically represent immunoblots performed on samples from different experiments (n = 2 or 3, indicated in figure legends). Band densities within each experiment were standardized to an arbitrary band density, and band densities for standardized immunoblots were compiled and expressed as averages (6high/low when n = 2 and 6SD when n = 3). Statistical analysis, analysis of variance, was performed with Origin Software (Origin Lab).
RESULTS
The continuous presence of serum in cultures of freshly isolated RCKs leads to a reduction in levels of the intracellular corneal crystallin proteins TKT and ALDH1A1. 32 Previously, we showed that the serum cytokine PDGF has the capacity to stimulate TKT loss from these cultures. 28 For a more comprehensive context, we sought to determine whether PDGF also stimulates loss of ALDH1A1, a putative corneal crystallin in the rabbit model. 33 RCKs were isolated, plated, washed after 1 day in culture, and then were left untreated or treated in serumfree media spiked with 100 ng/mL of PDGF for an additional 4 days. As determined by immunoblotting, PDGF treatment selectively reduced the TKT protein level as previously shown 28 ; in contrast, a new finding is that the ALDH1A1 protein level was unaffected ( Fig. 1) .
We next sought to identify the signal transduction pathways controlled by PDGF that leads to loss of TKT in corneal keratocytes. To begin, we assessed how antagonizing the PDGF receptor alters PDGF control over TKT in vitro. The pharmaceutical Gleevec (STI571, imatinib) is a proteintyrosine kinase inhibitor that interferes with signaling through the PDGF receptor. 34 RCKs in serum-free conditions were cultured in the absence or presence of 100 ng/mL of PDGF and 1 mM of Gleevec. As determined by immunoblotting, TKT levels were reduced in RCKs treated with PDGF, but not when the RCKs were exposed to Gleevec (Fig. 2) , consistent with regulation through the protein tyrosine kinase function of the PDGF receptor.
Following the activation of PDGF tyrosine kinase, PDGF's 2 main pathways for signaling have been described: the PI3K-activated Akt pathways and the ras-activated MAPK. 35 We treated RCKs without or with PDGF in the presence of known cell permeable inhibitors of signal pathway proteins relevant for PDGF signaling: PI3K (LY294002) and Akt (Triciribine); and 3 subfamilies of extracellular signal regulated MAPKs, p38 (SB203580), ERK (PD98059), and JNK (SP600125). As determined by immunoblotting, TKT protein levels when compared as a percent of control treatment (no PDGF) were reduced in RCKs exposed to PDGF, even in the presence of inhibitors of PI3K, ERK, and p38 (Fig. 3) . In contrast, TKT protein levels were unaffected (retaining the same levels as no PDGF control treatments) when cells were treated with PDGF in the presence of inhibitors to Akt and JNK. These data indicate that PDGF-stimulated loss of TKT involves activation of JNK and a PI3K-independent Akt pathway.
Previously, we reported that TKT loss during exposure to serum is associated with activation of the UPP. 32 In our next experiments, we directly assessed the role of the UPP in PDGF-stimulated TKT loss. RCKs were cultured without or with PDGF and clasto-lactacystin b-lactone, a cell permeable proteasome inhibitor. As determined by immunoblotting, PDGF-stimulated TKT protein loss was inhibited in the presence of clasto-lactacystin b-lactone (Fig. 4A ). In addition, RCKs treated without or with PDGF were assessed for TKT ubiquitination by immunoprecipitation with TKT and blotting for ubiquitin. The levels of ubiquitinated TKT were increased in RCKs treated with PDGF (Fig. 4B) . These results directly support the hypothesis that PDGF-stimulated loss of TKT occurs by degradation through the UPP.
Although PDGF clearly affects the levels of TKT protein accumulated within RCKs, it might affect TKT gene transcription and accumulation of TKT mRNA very differently. In the next set of experiments, we investigated the effects of PDGF on the accumulated levels of TKT mRNA. RCKs cultured under serum-free conditions were left untreated or treated with PDGF for 4 days. Total RNA was isolated, and quantitative reverse transcription-polymerase chain reaction was used to quantify mRNA levels for TKT, normalized to 18S ribosomal RNA levels. In striking contrast to results when protein was assayed, PDGF treatment of RCK did not appreciably alter TKT mRNA levels (Fig. 5A) .
Taken together, the preceding data indicate that PDGF mediates TKT protein loss without affecting mRNA levels. This suggests that RCKs might be able to re-accumulate TKT protein once PDGF is withdrawn. To test this hypothesis, RCKs cultured under serum-free conditions were left untreated or treated with PDGF for 4 or 7 days. In a subset of the cultures treated with PDGF for 4 days, PDGF was removed and RCKs were cultured for an additional 3 days. Total protein was isolated, and immunoblotting was used to quantify protein levels for TKT, normalized to b-actin levels. We found that in 7-day cultures from which PDGF was removed on the fourth day [d4(+)/d3(2)], TKT protein levels were comparable to those in cultures left untreated for 4 or 7 days. In addition, PDGF-induced loss of TKT is accentuated after 7 days of PDGF treatment when compared with 4 days of PDGF treatment (Fig. 5B) . 
DISCUSSION
In the cornea, fibrosis creates opacity and its contraction alters corneal shape and vision (reviewed in Strame et al 36 ) . Repair cells seem to be derived, at least in part, from resident keratocytes of the corneal stroma. [7] [8] [9] The specific goal of this Relative TKT mRNA calculated as threshold cycles for 18S subtracted from TKT. B, RCK cultured under serum-free conditions were left untreated (2) or treated (+) with PDGF for 4 (d4) or 7 (d7) days; or after 4 days, PDGF was removed and RCK were cultured for an additional 3 days [d4(+)/d3 (2)]. Representative immunoblot of cytoplasmic lysates probed with TKT and beta-actin antibody (top panel). Graph of immunoblot data (bottom panel). Relative TKT protein, a ratio of the TKT to the beta-actin band densities for each immunoblot (n = 2) expressed as average 6 high/low. study was to understand more about the molecular mechanisms mediating keratocyte transition to a "fibroblast" phenotype. We used a rabbit cell culture model characterized in our laboratory and focused on proteins called corneal crystallins, whose loss serves as a marker for the transition from keratocyte to fibroblast. The corneal crystallins accumulate to high levels in keratocytes of the quiescent cornea, but most of this accumulated protein is lost when keratocytes are activated in vitro by exposure to serum.
In the rabbit, the metabolic enzymes transketolase (TKT) and aldehyde dehydrogenase 1A1 (ALDH1A1) 26 are 2 of the major corneal crystallins. Previously, we showed that TKT loss in rabbit corneal keratocytes (RCK) is stimulated by the treatment of RCKs with PDGF or basic fibroblast growth factor (bFGF), and this loss is uncoupled from fibrotic markers whose expression is selectively stimulated by transforming growth factor-beta. 26 We showed here that treatment of RCKs with PDGF does not cause loss of the corneal crystallin ALDH1A1. 33 This result is consistent with reports that ALDH expression is controlled by transforming growth factor beta regulated pathways. 37 The finding provides additional support for the concept that the repair phenotype can be modulated to a more regenerative character by selectively interfering with specific regulatory pathways.
PDGF signals (reviewed in Tallquist and Kazlauskas 38 ) are mediated from PDGF receptors through PI3K/Akt 39 and MAPKs subfamilies, for example, p38, ERK, and JNK. 40, 41 We presented results indicating that PDGF stimulates TKT protein loss through the PDGF receptor because TKT loss did not occur in the presence of a PDGF receptor inhibitor, Gleevec. Additionally, PDGF-induced TKT loss occurred in the presence of a PI3K, ERK, and p38 inhibitor but was not noted in the presence of a specific inhibitor of Akt that did not impact PI3K and of JNK that did not impact p38. These results indicate that PDGF-induced loss of TKT through a signal pathway involving PI3K-independent Akt and JNK and are consistent with reports of a PI3K-independent Akt activation pathway 42 and of Akt cross talk with JNK. 43, 44 There is an ever-growing interest in an Akt pathway that is activated by mTOR, rather than PI3K, because deregulation of mTOR is an emerging theme in diverse human diseases (reviewed in Sarbassov et al 45 ) . Drugs that target mTOR, such as rapamycin, already have therapeutic uses as immunosuppressants. We have preliminary data that inhibition of mTOR abrogates PDGF-induced loss of TKT (A. J. LaGier and M. E. Fini, unpublished data). However, unlike other pathway inhibitors, rapamycin treatment led to an observable loss of RCK numbers, assumedly because rapamycin leads to irreversible cell cycle arrest. 46 We have previously noted that there is an association between TKT loss and proliferation, but concluded based on cell density studies that cell division is not sufficient to explain TKT loss. 28 In this regard, the preexisting TKT protein could passively be diluted as the cells divide in response to PDGF. For this to occur, PDGF induction of the Akt and JNK signal pathways would activate transcription factors, for example, FKHR, CREB, AP-1, that simply downregulate TKT gene transcription. Alternatively, RCK cultured in serum-free conditions undergo little cell division 11 and would therefore maintain preexisting TKT protein levels. Data presented here indicate that PDGF does not affect the TKT mRNA level indicating that PDGF does not simply turn "off" TKT production. In addition, analysis of the TKT promoter (accession: U90889; gi:2286041) did not reveal the presence of consensus sequences 47 appropriate for the FKHR, CREB, or AP-1 transcription factors. Together, these data indicated that PDGF-induced Akt and JNK directly impacted TKT protein rather than affecting TKT gene expression.
Several reports have recently indicated that AKT and JNK play a direct role in regulating protein degradation [48] [49] [50] through UPP, which we have previously shown to be involved in serum-induced loss of TKT. 32 We demonstrate here that RCK treated with PDGF in conjunction with clasto-lactacystin beta-lactone, a UPP inhibitor, retain TKT protein levels similar to untreated RCK. In addition, RCK treated with PDGF had enhanced levels of ubiquitinated TKT. These results confirm our previous findings with serum that UPP regulates TKT protein. We also noted that lactone treatment without PDGF led to an increase in TKT protein levels. Because lactones have been shown to inactivate protein kinases such as JNK, 51 these ancillary data further supports our findings that TKT loss involves JNK signaling. We suggest here that PDGF stimulates TKT protein loss because it directly compromises TKT protein stability through a PDGF receptor-driven signal pathway involving PI3K-independent Akt and JNK.
The findings that PDGF does not alter the ability of RCKs to produce TKT indicate that the RCKs retain the potential to reaccumulate TKT. Our data suggest that if PDGF is removed after it has effected a TKT loss, that is, day 4, the TKT protein levels approach TKT protein levels noted in untreated "quiescent" RCK. We did not observe a return of the quiescent morphology in these cells exposed to PDGF, which maintained an overall cell elongation 28 indicating that PDGF-induced changes to RCK phenotype are not reversible simply by removing PDGF.
In summary, we provide in this report a new insight into the molecular mechanisms for PDGF-induced keratocyte loss of the TKT crystallin. We suggest that PDGF-induced TKT loss is mediated through cross talk between Akt and JNK that directly compromises existing TKT protein stability. However, PDGF does not compromise new TKT protein production, and therefore, corneal keratocytes retain the potential to reaccumulate TKT. Our studies suggest that targeting of the PDGF receptor could be used to retain TKT within corneal repair cells and thus modulate repair outcomes after injury or surgical procedures in the cornea.
